The Value of PCI vs. CABG for Multivessel Coronary Artery Disease

Patients with multivessel coronary artery disease (CAD) who are eligible for both percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) face a nuanced decision. Although the clinical efficacy of both procedures is well established, limited data have been available on cost-effectiveness, quality of life, and return to work (Figure 1). Now, a prespecified analysis from the industry-supported FAME 3 trial addresses this gap. The trial involved 1500 adults with three-vessel CAD who were randomized to undergo either fractional flow reserve–guided PCI with second-generation drug-eluting stents or CABG.